| Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines … R Kullar, SL Davis, DP Levine, MJ Rybak Clinical infectious diseases 52 (8), 975-981, 2011 | 563 | 2011 |
| Epidemiology and Outcomes of Community-Associated Methicillin-Resistant Staphylococcus aureus Infection SL Davis, MB Perri, SM Donabedian, C Manierski, A Singh, D Vager, ... Journal of clinical microbiology 45 (6), 1705-1711, 2007 | 289 | 2007 |
| Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 … KP Murray, JJ Zhao, SL Davis, R Kullar, KS Kaye, P Lephart, MJ Rybak Clinical infectious diseases 56 (11), 1562-1569, 2013 | 210 | 2013 |
| Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases PS McKinnon, SL Davis European Journal of Clinical Microbiology and Infectious Diseases 23, 271-288, 2004 | 179 | 2004 |
| Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa JM Pogue, KS Kaye, MP Veve, TS Patel, AT Gerlach, SL Davis, ... Clinical Infectious Diseases 71 (2), 304-310, 2020 | 152 | 2020 |
| High‐dose daptomycin for treatment of complicated gram‐positive infections: a large, multicenter, retrospective study R Kullar, SL Davis, DP Levine, JJ Zhao, CW Crank, J Segreti, G Sakoulas, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31 (6 …, 2011 | 148 | 2011 |
| A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis R Kullar, AM Casapao, SL Davis, DP Levine, JJ Zhao, CW Crank, ... Journal of Antimicrobial Chemotherapy 68 (12), 2921-2926, 2013 | 133 | 2013 |
| Characteristics of Patients With Healthcare-Associated Infection Due to SCCmec Type IV Methicillin-Resistant Staphylococcus aureus SL Davis, MJ Rybak, M Amjad, GW Kaatz, PS McKinnon Infection Control & Hospital Epidemiology 27 (10), 1025-1031, 2006 | 124 | 2006 |
| Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15–20 mg/L suggested by the vancomycin consensus guidelines R Kullar, SN Leonard, SL Davis, G Delgado Jr, JM Pogue, KA Wahby, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31 (5 …, 2011 | 118 | 2011 |
| Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy AM Casapao, SL Davis, VO Barr, KP Klinker, DA Goff, KE Barber, ... Antimicrobial agents and chemotherapy 58 (5), 2541-2546, 2014 | 117 | 2014 |
| Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes SL Davis, PS McKinnon, LM Hall, G Delgado Jr, W Rose, RF Wilson, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27 (12 …, 2007 | 116 | 2007 |
| Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections EJ Zasowski, KC Claeys, AM Lagnf, SL Davis, MJ Rybak Clinical Infectious Diseases 62 (10), 1242-1250, 2016 | 113 | 2016 |
| Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections SCJ Jorgensen, TD Trinh, EJ Zasowski, AM Lagnf, S Bhatia, SM Melvin, ... Open forum infectious diseases 6 (12), ofz522, 2019 | 108 | 2019 |
| Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort R Kullar, SL Davis, TN Taylor, KS Kaye, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32 (3 …, 2012 | 108 | 2012 |
| Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Bloodstream Isolates in Urban Detroit T Chua, CL Moore, MB Perri, SM Donabedian, W Masch, D Vager, ... Journal of clinical microbiology 46 (7), 2345-2352, 2008 | 101 | 2008 |
| Multicenter study of high-dose daptomycin for treatment of enterococcal infections AM Casapao, R Kullar, SL Davis, DP Levine, JJ Zhao, BA Potoski, ... Antimicrobial agents and chemotherapy 57 (9), 4190-4196, 2013 | 96 | 2013 |
| Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus bloodstream infection AM Casapao, SN Leonard, SL Davis, TP Lodise, N Patel, DA Goff, ... Antimicrobial agents and chemotherapy 57 (9), 4252-4259, 2013 | 93 | 2013 |
| Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties SCJ Jorgensen, NJ Mercuro, SL Davis, MJ Rybak Infectious Diseases and Therapy 7, 197-217, 2018 | 91 | 2018 |
| Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis AM Casapao, TP Lodise, SL Davis, KC Claeys, R Kullar, DP Levine, ... Antimicrobial agents and chemotherapy 59 (6), 2978-2985, 2015 | 91 | 2015 |
| Epidemiology, risk factors, and outcomes of Candida albicans versus non-albicans candidemia in nonneutropenic patients SL Davis, JA Vazquez, PS McKinnon Annals of Pharmacotherapy 41 (4), 568-573, 2007 | 89 | 2007 |
